ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

@article{Maertens2016ECILGF,
  title={ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.},
  author={Johan Maertens and Simone Cesaro and Georg Maschmeyer and Hermann Einsele and J. Peter Donnelly and Alexandre Alanio and Philippe M Hauser and Katrien Lagrou and Willem J G Melchers and Jannik Helweg-Larsen and O. Martı́nez Matos and St{\'e}phane Bretagne and Catherine Cordonnier},
  journal={The Journal of antimicrobial chemotherapy},
  year={2016},
  volume={71 9},
  pages={2397-404}
}
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice

ML Lobo, F Esteves, B de Sousa
PLoS One 2013; • 2013

Similar Papers

Loading similar papers…